Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Goserelin 10.8mg vs 3.6mg in Premenopausal Breast Cancer
CTR20180973Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of goserelin in breast cancer, sponsored by AstraZeneca. Started Jul 2018; status: terminated.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20180973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180973.